All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
PARADIGM-PV: Ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
|
Phlebotomy and aspirin are often used to treat patients with low-risk PV; however, data from the phase II Low-PV study (NCT03003325) demonstrated that this intervention may be inadequate. Disease-modifying treatments appear to be beneficial for patients with PV, regardless of risk category. Ropeginterferon alfa-2b (ropeg) is a novel INF-based therapy with favorable dosing schedules, and a higher ropeg starting-dose (250 µg) with simpler dose titrations has demonstrated potent disease-modifying effect in terms of molecular response induction. Flexible dose adjustments and schedule changes with longer intervals (e.g. once every 3–4 weeks after stabilization of treatment response) offer improved convenience for patients, with improved disease outcomes. PARADIGM-PV (NCT06290765) is a randomized, multicenter phase IV study designed to assess the efficacy and safety of ropeg in patients with low- or high-risk PV. Yacoub et al. detail the study rationale, design, and outcome measures in a recent publication in Annals of Hematology. |
| Key learnings |
| Approximately 70 patients with PV will be enrolled. The study period will be 112 weeks, with a 32-week main treatment phase and an 80-week extension treatment phase, plus an additional 4-week safety follow-up phase. |
| The primary goal is to assess the efficacy of ropeg with a higher starting dose (250 µg) and flexible dosing schedules in reducing phlebotomy dependence, while maintaining Hct values in patients with both low- and high-risk PV. |
| The primary endpoint will be the proportion of patients achieving a response at Week 20–32. Secondary endpoints will include CHR, molecular response, symptom improvement, maintenance of median Hct <45% without PD, and safety. |
| The higher starting dose with subsequently reduced-intensity/stringency maintenance therapy aims to rapidly achieve maximal CHRs and molecular responses and minimize neoplastic cells carrying JAK2 mutations in order to suppress disease progression. |
Abbreviations: CHR, complete hematologic response; Hct, hematocrit; INF, interferon; MPN, myeloproliferative neoplasm; PD, progressive disease; PV, polycythemia vera.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
The phase III SURPASS-ET trial demonstrated the efficacy of ropeginterferon alfa-2b (ropeg) as a second-line treatment for essential thrombocythemia (ET). Of your patients with ET, what proportion are you currently treating with ropeg?
